The biotech company Verve Therapeutics launched the study with the aim of using base editing to treat a genetic condition that causes high cholesterol and increases a person's risk of developing cardiovascular disease.
New methods enable deep coverage of the blood and tissue proteome, expand capabilities for dynamic biomarker discovery to include metabolites, lipids, and proteins
This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
CRISPR-Cas9 editing leads to widespread loss of the targeted chromosome in human T cells, but scientists recently discovered a way to prevent such loss.